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Abstract
Background—Men who have sex with men (MSM) are at high risk of acquiring HIV infection 
following diagnosis with other sexually transmitted infections (STIs). Identifying the STIs 
associated with the greatest risk of subsequent HIV infection could help target prevention 
interventions, particularly pre-exposure prophylaxis (PrEP).
Methods—Using matched HIV and STI surveillance data from Washington State from 
1/1/2007–6/30/2013, we calculated the incidence of new HIV diagnoses following different STI 
diagnoses among MSM. Men entered observation at the time of their first STI diagnosis during the 
study period and exited at HIV diagnosis or 6/30/2013. Cox proportional hazards regression was 
used to conduct a global comparison of rates.
Results—From 1/1/2007–6/30/2013, 6577 HIV-negative MSM were diagnosed with 10,080 
bacterial STIs at 8,371 unique time points and followed for 17,419 person-years. 280 (4.3%) men 
were subsequently diagnosed with HIV infection for an overall incidence of 1.6 per 100 person-
years (95%CI=1.4–1.8). The estimated incidence of HIV diagnoses among all MSM in the state 
was 0.4 per 100 person-years. MSM were at the greatest risk of HIV diagnosis after being 
diagnosed with rectal gonorrhea (HIV incidence = 4.1 per 100 person-years), followed by early 
syphilis (2.8), urethral gonorrhea (1.6), rectal chlamydial infection (1.6), pharyngeal gonorrhea 
(1.1), late syphilis (1.0), and urethral chlamydial infection (0.6) [p<0.0001 overall].
Conclusions—MSM diagnosed with rectal gonorrhea and early syphilis were at the greatest risk 
of being diagnosed with HIV infection post-STI diagnosis. These men should be prioritized for 
more intensive prevention interventions, including PrEP.
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INTRODUCTION
Men who have sex with men (MSM) are disproportionately affected by HIV and other 
sexually transmitted infections (STIs). Being diagnosed with an STI is among the most 
consistent and longstanding risk factors associated with HIV acquisition1–3. The elevated 
risk of HIV acquisition among MSM with bacterial STIs reflects some combination of 
increased susceptibility2–12, sustained risk behaviors, and sexual network factors. The 
advent of pre-exposure prophylaxis (PrEP) has created a new impetus for identifying the 
populations of MSM at greatest risk for HIV infection. PrEP is efficacious13 but expensive, 
and cost-effectiveness analyses have consistently found that it is only cost-effective when 
targeted to the highest risk men14–18. Previous studies suggest that HIV-negative MSM 
diagnosed with early syphilis, rectal gonorrhea, and rectal chlamydial infection may be at 
particularly high risk of subsequent HIV infection19–22. However, these studies did not 
estimate HIV incidence for all bacterial STIs by anatomic site or stage of infection, were 
limited to STD clinics or study populations, did not estimate the proportion of all HIV 
infections among MSM occurring in men with a recent STI diagnosis, and measured only 
the incidence of HIV diagnosis rather than HIV infection. To identify MSM for 
prioritization of intensive HIV prevention interventions, including PrEP, we used matched 
HIV/STI surveillance data from Washington State to examine the incidence of new HIV 
diagnoses following STI diagnoses among MSM statewide and estimate the incidence of 
new infection among MSM diagnosed at an STD clinic and large community-based 
HIV/STI testing site. We used these findings to estimate the number of men who would 
need to receive PrEP to avert one HIV infection directly. Finally, based on a prior analysis 
among MSM in our STD clinic suggesting that substance use was associated with HIV risk 
even when controlling for STI diagnosis23, we assessed whether the risk of subsequent HIV 
diagnosis after STI diagnoses was modified by substance use.
MATERIALS AND METHODS
Data Sources
We used matched HIV/STI surveillance data from Washington State from January 1, 2007-
June 30, 2013. STI surveillance and partner services data are routinely matched with HIV 
surveillance data from the Enhanced HIV/AIDS Reporting System (eHARS) through a two-
step process. First, an automated probabilistic matching algorithm of all persons in the STI 
surveillance system and all individuals in eHARS based on legal and alias names, date of 
birth, and sex is run weekly. Second, Washington State Department of Health staff conduct a 
monthly manual review of STI cases not matched to eHARS but with an indication of HIV 
infection in STI surveillance or partner services data.
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HIV-negative or unknown status MSM diagnosed with syphilis of known stage or urethral, 
rectal, or pharyngeal gonorrhea or chlamydial infection were included in this analysis (98% 
of reported infections). Men who reported sex with men in the last year during partner 
services interviews, whose provider indicated male sex partners on the case report, or who 
were diagnosed with rectal gonorrhea or chlamydial infection were defined as MSM. 
(Medical providers in Washington State are legally required to complete a case report form 
for each person they diagnose with syphilis, gonorrhea, or chlamydial infection. This form 
includes gender of sex partners, which was available for 79% of all bacterial STI cases in 
men during the study period.) In order to include only HIV-negative or unknown status 
MSM, men whose HIV diagnosis date in eHARS preceded the date of their first STI 
diagnosis during the study period or who were diagnosed with HIV infection or reported a 
prior HIV diagnosis at the time of their first STI diagnosis during this period were excluded.
Analyses
Incidence of HIV diagnosis by STI type—We calculated incidences of HIV diagnosis 
following STI diagnosis defined by pathogen and anatomic site or stage of infection (STI 
type) by dividing the total number of new HIV diagnoses within a given STI stratum by the 
total time at risk within that stratum (see below for a description of how we defined these 
strata). We conducted a global comparison of incidences using Cox proportional hazards 
regression including all STI types as a time-varying covariate. The time scale for the Cox 
model was calendar time. Men entered observation on the date of their first STI diagnosis 
during the study period and exited either on the date of HIV diagnosis from eHARS or June 
30, 2013 (administrative censoring). Prior to the analyses, we created a hierarchy of STI 
types by calculating the incidence of HIV diagnosis following STI diagnosis separately for 
each type and ranking them in descending order as follows: rectal gonorrhea, early syphilis 
(primary, secondary, and early latent), rectal chlamydial infection, urethral gonorrhea, late 
syphilis, pharyngeal gonorrhea, urethral chlamydial infection, and pharyngeal chlamydial 
infection. Because interventions would be targeted based on an individual’s highest-risk 
STI, MSM diagnosed with concurrent infections or infections at ≥1 site were assigned the 
higher-risk STI for that time point, and men with multiple infections over time could move 
up, but not down, the STI hierarchy. In a parallel analysis, we examined the incidence of 
HIV diagnosis following co-infections with the three highest risk STI types by incorporating 
them into the hierarchy as follows: rectal gonorrhea and early syphilis, rectal chlamydial 
infection and early syphilis, and rectal gonorrhea and rectal chlamydial infection.
Incidence of HIV diagnosis by substance use—Partner services staff elicit substance 
use (methamphetamine, inhaled nitrites, and erectile dysfunction [ED] drugs) in the year 
prior to STI diagnosis during interviews. We calculated the incidence of HIV diagnosis 
following STI diagnosis by substance use by dividing the total number of new HIV 
diagnoses within a given substance use stratum, by the total time at risk within that stratum. 
We compared incidences using Cox proportional hazards regression with substance use and 
STI types as time-varying covariates. The time scale for the Cox model was calendar time. 
Men entered observation on the date of their first STI diagnosis during the study period at 
which substance use was ascertained and exited on their HIV diagnosis date or June 30, 
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2013. Men diagnosed with multiple STIs over time could be recategorized from non-users to 
users of substances, but not from users to non-users.
Comparison with general population of MSM—For comparison, we estimated the 
incidence of HIV diagnosis among sexually-active HIV-negative MSM in Washington State 
during the study period. We used the number of new HIV diagnoses among MSM in 
eHARS as the numerator and 3.9% of men age 15 and older from Washington State census 
estimates (based on U.S. Centers for Disease Control and Prevention estimate of proportion 
of men who have had sex with men in the past 5 years24) minus the number of MSM known 
to be living with HIV from eHARS as the denominator. Because HIV risk in Washington is 
concentrated among MSM under 65 years of age, we also compared the incidence of HIV 
diagnosis post-STI diagnosis among MSM aged 15–64 (99.5% of STI cases; 99% of HIV 
diagnoses among MSM with STIs) to the incidence among sexually-active HIV-negative 
MSM in Washington State aged 15–64 (99.6% of HIV cases among MSM).
Number needed to treat (NNT) and population-level impact—We calculated the 
NNT with PrEP for one year to prevent one HIV infection among PrEP recipients as 
follows: 1 ÷ (HIV incidence × PrEP effectiveness)25. To address differences in PrEP 
effectiveness due to adherence, we used three efficacy estimates from iPrEx: the overall 
estimate of 44% reduction in HIV acquisition, the estimate among MSM reporting ≥90% 
adherence of 73%, and the estimate among MSM with detectable blood levels of 
emtricitabine, tenofovir, or their metabolites of 92%13.
To provide an upper bound for the potential direct population-level impact of a prevention 
intervention targeted towards MSM diagnosed with bacterial STIs, we calculated the 
proportion of HIV cases reported among MSM in the last two years of the study period who 
had been diagnosed with an STI in the two years prior to HIV diagnosis.
Sensitivity analyses—The primary analysis has the potential to underestimate the true 
HIV incidence and overestimate NNTs because men who were not tested for HIV infection 
at the time of STI diagnosis may have been misclassified as uninfected, passive follow-up 
may fail to identify new HIV infections, and incidence of HIV diagnosis is sensitive to the 
lag between HIV acquisition and diagnosis. To address these limitations, we conducted an 
analysis among STI cases diagnosed at two publicly-funded HIV/STI testing programs 
(Public Health–Seattle & King County STD Clinic and Gay City) unless partner services 
data indicated that cases were not HIV tested at STI diagnosis. At these sites, near-universal 
HIV testing at STI diagnosis reduced misclassification of persons at study entry, and 
frequent HIV testing should diminish the influence of passive follow-up and the lag between 
HIV acquisition and diagnosis. In addition, we calculated an incidence of HIV infection 
(rather than diagnosis) by estimating the infection date as the midpoint between the last 
negative and first positive HIV test from surveillance or partner services data. Men entered 
observation on the date of their first STI diagnosis at these sites during the study period and 
exited on the date of HIV infection or June 30, 2013.
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Analyses were conducted using SAS 9.3 (SAS Institutes, Cary, NC) and Stata 11.0 (Stata 
Corp, College Station, TX). These analyses were conducted as part of public health program 
activities and not considered human subjects research.
RESULTS
From January 2006–June 2013, 10,080 bacterial STIs were reported among 6,577 HIV-
negative or unknown status MSM in Washington State at 8,371 unique time points. These 
men were followed for a total of 17,419 person-years (median=2.4 years, interquartile 
range=1.1 to 4.0), and 280 (4.3%) were diagnosed with HIV infection during follow-up for 
an overall incidence of 1.61 diagnoses per 100 person-years (95% confidence interval 
[CI]=1.43–1.81), four times greater than the estimated incidence of diagnoses among all 
HIV-negative MSM statewide (0.41 per 100 person-years). Restricted to MSM ages 15–64, 
incidence of HIV diagnosis was 1.60 per 100 person-years among men following STI 
diagnoses, more than three-fold higher than the 0.48 per 100 person-years among all HIV-
negative MSM. Sociodemographic characteristics at each individual’s initial reported STI 
during the study period and HIV testing history are presented in Table 1.
The incidence and cumulative hazard of HIV diagnosis following STI diagnosis by STI type 
are presented in Table 2A and Figure 1, respectively. MSM were at the greatest risk of 
acquiring HIV after diagnosis with rectal gonorrhea (incidence=4.1 per 100 person-years), 
followed by early syphilis (2.8), urethral gonorrhea (1.6), rectal chlamydial infection (1.6), 
pharyngeal gonorrhea (1.1), late syphilis (1.0), and urethral chlamydial infection (0.6) 
[p<0.0001 overall]. Consequently, the NNT with PrEP was lowest for rectal gonorrhea and 
early syphilis (Table 2A; Figure 2A). If PrEP reduces the risk of acquiring HIV by 44%, 55 
and 80 MSM diagnosed with rectal gonorrhea and early syphilis, respectively, would need to 
be treated with PrEP for one year to prevent one new infection among PrEP recipients. 
Using the highest estimate of PrEP efficacy (92% risk reduction), 26 and 38 MSM with 
rectal gonorrhea and early syphilis would need to be treated.
Men were concurrently diagnosed with more than one bacterial pathogen at 810 time points 
(9.7% of 8,371), including 24 early syphilis-rectal gonorrhea, 29 early syphilis-rectal 
chlamydia, and 251 rectal gonorrhea-rectal chlamydia co-infections. The incidences of HIV 
diagnosis following these co-infections were the greatest we observed: 11.8, 10.8, and 5.9 
per 100 person-years, respectively.
Table 2B and Figure 2B describe the HIV incidence and NNTs from the sensitivity analysis 
conducted among STI cases from publicly-funded testing programs and estimating the 
incidence of HIV infection. Overall, HIV incidence following STI diagnosis was 2.48 per 
100 person-years, a 54% increase from 1.61 in the primary analysis. The absolute difference 
between estimated incidence of diagnosis and infection was small for gonococcal infections 
regardless of anatomic site and urethral chlamydial infection, but higher for early and latent 
syphilis and rectal chlamydial infection. Despite these differences, MSM continued to be at 
greatest risk of acquiring HIV after diagnosis with rectal gonorrhea (incidence=4.4 per 100 
person-years) and early syphilis (3.7).
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From July 2011–June 2013, 736 MSM were diagnosed with HIV infection in Washington 
State, of whom 104 (14%) had a history of bacterial STI in the two years prior to HIV 
diagnosis, including 47 (6.4%) with a history of early syphilis or rectal gonorrhea (Figure 3).
Among 3715 men (56% of total) for whom information regarding substance use was 
available from ≥1 STI diagnosis, 306 (8.2%) reported using methamphetamine, 632 (17%) 
inhaled nitrites, and 401 (11%) ED medications in the year prior to STI diagnosis. In 
bivariable analyses, men who reported using each of these substances experienced greater 
incidences of HIV diagnosis following STI diagnosis than men who denied using these 
substances (methamphetamine=5.09 vs. 1.65 per 100 person-years, inhaled nitrites=4.40 vs. 
1.53, ED drugs=3.91 vs. 1.71; p<0.001 for all). In multivariable analyses including all three 
substances and STI type, methamphetamine and inhaled nitrite use remained significantly 
associated with incidence of HIV diagnosis [adjusted hazard ratios=1.92 (95%CI=1.29–
2.84) and 2.2 (1.6–3.1), respectively; p<0.001 for both].
DISCUSSION
In Washington State, MSM diagnosed with any bacterial STI experienced three- to four-fold 
greater incidence of HIV diagnosis following their STI than MSM overall, with the greatest 
risks observed among MSM diagnosed with rectal gonorrhea and early syphilis or reporting 
methamphetamine or inhaled nitrite use. However, only one in every seven MSM newly 
diagnosed with HIV infection had been diagnosed with a bacterial STI in the two years prior 
to HIV diagnosis, and only 6.4% had a recent history of rectal gonorrhea or syphilis. These 
results suggest that targeting HIV prevention interventions to MSM diagnosed with STIs, 
specifically rectal gonorrhea and early syphilis and methamphetamine or inhaled nitrite 
users, has the potential to reach very high risk men but will only directly affect a relatively 
small subset of MSM who will ultimately acquire HIV infection. These findings highlight 
the potential value of using specific STIs to target resource-intensive interventions such as 
PrEP but suggest how such a highly-targeted approach might have limited direct population-
level impact.
This population-based study supports conclusions from previous studies in clinical and 
research settings that MSM with rectal infections and early syphilis are at extremely high 
risk of subsequently acquiring HIV, though our absolute risk estimates are lower than those 
previously reported19–22. Similar to a study in New York City STD clinics19, we observed 
higher HIV incidence following rectal gonorrhea than rectal chlamydia diagnosis, but HIV 
incidence in both groups was greater in New York City than in Washington State (7.1 vs. 4.1 
per 100 person-years for rectal gonorrhea; 5.9 vs. 1.6 for rectal chlamydial infection). In 
iPrEx21, which was conducted primarily in South America, MSM experienced an HIV 
incidence of 8.0 per 100 person-years following syphilis diagnosis, more than twice the 2.8 
per 100 person-years observed among MSM in Washington State. Variations in absolute risk 
across studies may reflect differences in HIV incidence among MSM in these geographic 
areas, differences in risk in the study populations (i.e. population-based vs. STD clinic 
clients or study participants), or in the case of iPrEx, greater ascertainment of infection 
through active follow-up.
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The relationship between HIV and STI acquisition is complex and multidirectional. Some 
evidence suggests that genital tract inflammation caused by bacterial STIs increases the risk 
of HIV transmission by increasing HIV shedding by HIV-infected partners and causing 
breaches in the genital tract epithelium and recruitment of targets cells to this area in HIV-
susceptible partners.2–12 However, these biological mechanisms because they require the 
pathogen to be present at the time of HIV exposure. Rather, our findings are likely a result 
of the association between different STI and subsequent behaviors and sexual network 
factors that result in exposure to HIV. Rectal infections are direct markers of condomless 
receptive anal sex, which is associated with a greater risk of HIV acquisition than oral or 
insertive anal sex26–28, and because the syphilis epidemic in the U.S. and other developed 
countries is concentrated among MSM living with HIV29, early syphilis may be a marker of 
condomless sex within sexual networks including high-risk MSM living with HIV. It is also 
possible that men at higher risk of acquiring HIV are more likely to seek STI screening in 
general, in clinical settings where extragenital testing is available, or are more likely to 
recognize or seek care in response to symptoms. Exploring the reasons that STI diagnoses 
predict future HIV acquisition may help identify additional targets for prevention 
interventions.
PrEP implementation is resource-intensive, and several cost-effectiveness analyses have 
found that, despite its potential impact on HIV incidence, providing PrEP to general 
populations of MSM in the U.S. and Australia is probably not cost-effective at current 
medication costs14–17,30. Prioritizing sub-populations of MSM with higher HIV incidence, 
however, may be cost-effective in some situations14–18. With that in mind, we designed our 
analysis to identify populations at high risk for HIV infection for PrEP prioritization and 
assess the potential population-level effects of such an approach. NNTs can be used to 
compare the effectiveness of targeting interventions to subpopulations with different levels 
of risk, intervention adherence, and other factors. Similar to an analysis from iPrEx31, 
relatively few MSM diagnosed with syphilis would need to be treated with PrEP to prevent 
one new HIV infection among PrEP recipients, but the proportion of HIV infections 
occurring in men with a prior syphilis diagnosis was small. In iPrEx, condomless receptive 
anal sex with a partner of any HIV status was associated with a similar NNT but a much 
larger population attributable fraction, suggesting that offering PrEP to all men reporting 
condomless receptive anal sex would have a larger population-level impact than offering it 
to MSM with rectal gonorrhea or early syphilis alone at a similar cost per case directly 
averted. Our study does not directly address the relative benefits of targeting MSM with 
syphilis or rectal gonorrhea versus all MSM who engage in condomless receptive anal sex. 
However, in a prior analysis among MSM attending an STD clinic, we found that 
condomless receptive anal sex was not associated with HIV incidence when adjusting for 
diagnosis with a bacterial STI and methamphetamine or inhaled nitrite use in the prior 
year23, suggesting that NNTs may be substantially higher in a group defined solely by 
condomless receptive anal sex and not stronger risk factors. Neither the iPrEx study 
population (primarily South American MSM) nor MSM in Washington State is likely to 
provide accurate estimates of HIV risk for prioritizing PrEP among MSM in other settings. 
PrEP targeting criteria should be context-specific and may not be appropriate in settings 
where HIV risk in the general population of MSM is extremely high. Regardless, offering 
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PrEP to MSM diagnosed with higher-risk STIs may help increase the cost-effectiveness of 
PrEP programs.
This study has several limitations. First, without being able to measure the true date of HIV 
infection, the primary analysis relied on the date of the first positive test. This approach 
likely led us to underestimate the true incidence of HIV infection post-STI diagnosis for 
several reasons: the lag between HIV acquisition and diagnosis; failure to identify infections 
in men who did not test during follow-up; and underascertainment of infections in men who 
migrated out of the area. Our approach may also have misclassified HIV-infected MSM who 
tested HIV-negative during acute infection or did not test at the time of their initial STI 
diagnosis, potentially leading to an overestimate of the true HIV incidence in the population. 
To partially address these limitations, we undertook an analysis restricted to MSM 
diagnosed with STIs in large publicly-funded testing programs and estimated time of HIV 
infection based on cases’ HIV testing history. NNTs were somewhat lower in this analysis, 
suggesting that relying on HIV diagnosis as a surrogate for HIV infection led us to 
overestimate NNTs in our main analysis. Some of this variation, however, may reflect 
differences between persons seen in an STD clinic or community-based program and the 
general population. In addition, many bacterial STIs in MSM are asymptomatic, and it is 
possible that the elevated rate of HIV diagnoses we observed overall and following specific 
STI types reflects a pattern of more frequent testing in men with these STIs rather than a true 
elevation of HIV risk. While we cannot completely exclude this possibility, the fact that 
some asymptomatic STIs (e.g. urethral chlamydial infection and pharyngeal gonorrhea) 
were associated with a relatively low risk of subsequent HIV acquisition argues against the 
idea that our findings are simply a result of ascertainment bias. Moreover, from a public 
health perspective, our findings clearly identify groups at high risk for HIV acquisition that 
could benefit from PrEP. Missing data regarding substance use may affect estimates of the 
association with subsequent HIV diagnosis and limited our ability to calculate the potential 
population-level effects of such prioritization. Furthermore, our NNTs were limited to the 
direct effects of PrEP on individuals taking the medications and did not take into account 
potential infections averted among partners and sexual networks. Lastly, the utility of PrEP 
efficacy estimates from iPrEx for calculating NNTs may be affected by differences in 
behavior and adherence between MSM in Washington State versus the study population due 
to differential knowledge regarding PrEP effectiveness, access to intensive risk-reduction or 
adherence counseling, or frequency and intensity of HIV exposures.
In conclusion, we found that MSM with rectal gonorrhea and syphilis and MSM with STIs 
who use methamphetamine or inhaled nitrites were at very high risk for future HIV 
infection. Gonorrhea and syphilis are reportable throughout the U.S. and, insofar as 
gonococcal infections are reportable with data on anatomic site of infection, the population 
with these infections is readily defined and could be targeted by public health agencies for 
specific prevention outreach, particularly promoting frequent HIV/STI testing and PrEP. At 
a minimum, clinicians should discuss PrEP as an HIV prevention option with MSM with 
rectal gonorrhea, early syphilis, or who report methamphetamine or inhaled nitrite use 
concurrent with any STI diagnosis.
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A population-based study in Washington State found that men who have sex with men 
were at very high risk of acquiring HIV following diagnosis with rectal gonorrhea or 
early syphilis.
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Figure 1. Cumulative hazard of HIV diagnosis following bacterial sexually transmitted infections 
(STI)
GC = gonorrhea. CT = chlamydial infection.
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Figure 2. Number needed to treat (NNT) with HIV pre-exposure prophylaxis to directly prevent 
one new HIV infection by sexually transmitted infection type
Panel A: Primary analysis – Estimated from incidence of HIV diagnosis in Washington State
Panel B: Sensitivity analysis – Estimated from incidence of HIV infection among MSM 
diagnosed at publicly funded HIV/STI testing programs
MSM = men who have sex with men. GC = gonorrhea. CT = chlamydial infection. PrEP = 
HIV pre-exposure prophylaxis.
This figure presents estimates of the number of HIV-negative MSM with each infection that 
would need to be treated with PrEP for one year in order to prevent one HIV infection 
among PrEP recipients (NNT) based on three estimates of PrEP effectiveness from iPrex17: 
overall (44%; ■), with at least 90% adherence (73%; ●), and with detectable blood levels of 
PrEP drug (92%; ▲). Panel A shows NNTs estimated from the incidence of HIV diagnosis 
following STI diagnoses among all MSM in Washington State (primary analysis). Panel B 
presents estimates from the incidence of HIV infection among MSM diagnosed at publicly 
funded HIV/STI testing programs (sensitivity analysis). The date of HIV infection was 
estimated as the midpoint between the last negative and first positive HIV test from HIV 
surveillance, HIV partner services, or STI partner services data.
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Figure 3. Proportion of 736 MSM newly diagnosed with HIV infection July 2011-June 2013 with 
a reported sexually transmitted infection diagnosis in the 2 years prior to HIV diagnosis
GC = gonorrhea. CT = chlamydial infection.
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Table 1
Characteristics of 6577 HIV-negative men who have sex with men diagnosed with bacterial sexually 
transmitted infections (STI) from January 2007 to June 2013 in Washington State
Characteristics at initial STI diagnosis during study period and HIV testing history Median or Number IQR or %
Age (years) 28 23 to 37
Race/Ethnicity
 White 3966 60%
 Hispanic/Latino (any race) 969 15%
 Black 575 9%
 Asian/Pacific Islander 394 6%
 Native American/Alaska Native 65 1%
 Multiple race 143 2%
 Unknown 420 6%
King County residence 4202 64%
HIV testing status*
 Tested HIV-negative at the time of or following initial STI diagnosis 3371 51%
 Tested HIV-negative prior to initial STI diagnosis or at unknown time 865 13%
 Reported no prior HIV test 237 4%
 No HIV testing history available 2105 32%
Years of follow-up 2.4 1.1 to 4.0
HIV diagnosis during follow-up 280 4.3%
 Tested HIV-negative at time of or following initial STI diagnosis and prior to HIV diagnosis^ 221 79%
IQR = Interquartile range.
*
Based on self-reported HIV testing history from STI partner services interviews.
^
Based on self-reported HIV testing history or medical record review from HIV surveillance, HIV partner services, or STI partner services.
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